Holdings
DAFNA Capital Management LLC
As of Jun 30, 2026, DAFNA Capital Management LLC reported 70 positions worth US$424M. Largest: Revolution Medicines, Inc., Stereotaxis, Inc. and Nektar Therapeutics. What it bought and sold, with each filing.
| Company | Shares | Value as reported | Change | As of |
|---|---|---|---|---|
| Revolution Medicines, Inc. | 563K | US$105M | −18,048 | Jun 30, 2026 |
| Stereotaxis, Inc. | 13.7M | US$23.5M | no change | Jun 30, 2026 |
| Nektar Therapeutics | 318K | US$22.2M | +153K | Jun 30, 2026 |
| Denali Therapeutics Inc. | 739K | US$19M | +421K | Jun 30, 2026 |
| Ideaya Biosciences, Inc. | 497K | US$18.5M | +20,500 | Jun 30, 2026 |
| Atricure, Inc. | 597K | US$16.7M | no change | Jun 30, 2026 |
| Xenon Pharmaceuticals Inc. | 251K | US$15.1M | no change | Jun 30, 2026 |
| Cytokinetics, Incorporated | 172K | US$14.7M | −45,499 | Jun 30, 2026 |
| Arcus Biosciences, Inc. | 442K | US$13.6M | −2,000 | Jun 30, 2026 |
| Neurocrine Biosciences, Inc. | 57,769 | US$9.74M | −12,846 | Jun 30, 2026 |